Compound d16 reduces tumor growth and overcomes therapeutic resistance in mutant p53-bearing cancers

Researchers at Baylor College of Medicine have developed a new compound called d16 that can reduce tumor growth and overcome therapeutic resistance in mutant p53-bearing cancers in the lab. The findings, published in the journal Cancer Research Communications, open opportunities for new combination therapies for these difficult-to-treat cancers.